

**A STUDY ON GENTAMICIN IMPREGNATED  
BIOMATERIALS FOR TREATING INDUCED-  
OSTEOMYELITIS IN THE NEW ZEALAND WHITE  
RABBIT ANIMAL MODEL**

**BY**

**AHMAD HAFIZ ZULKIFLY**

**A thesis submitted in fulfilment of the requirement for the  
degree of Doctor of Philosophy in Medical Sciences**

**Kulliyyah of Medicine  
International Islamic University Malaysia**

**AUGUST 2021**

## ABSTRACT

The treatment of osteomyelitis is still a major challenge in orthopaedics. A study of osteomyelitis and infection requires the use of a suitable animal model. The New Zealand White Rabbit (NZWR) is an acceptable experimental model that can be used for local delivery of antibiotics in osteomyelitis treatment as it can mimic the disease process in humans. The objectives of this study were to create osteomyelitis in the rabbit femurs and to analyse the treatment given via gentamicin impregnated with biomaterials beads. Thirty-six (36) NZWRs were used in the study. They were divided into two groups [Hydroxyapatite (HA) and calcium sulphate (CaSO<sub>4</sub>)] with four subgroups 3-, 6-, 12-, and 26-weeks intervals. There were two surgeries performed for each NZWR. The first was to induce the osteomyelitis by inoculating *Staphylococcus aureus* in the distal of the animal, and the second surgery was for debridement and biomaterial impregnated antibiotics implantation. The responses of the treatments (gentamicin impregnated with HA and CaSO<sub>4</sub>) were evaluated through gross appearance, radiograph, micro-CT, microbiological, and histological examination. The rabbits were sacrificed accordingly to evaluate the healing process of the affected bone. The results showed osteomyelitis changes in all rabbits after the inoculation of the bacteria at 3 weeks. The rabbits' weights reduced after three weeks of bacteria inoculation following the treatment with biomaterial impregnated antibiotics, they showed significant increase in weights at 12 and 26 weeks in both groups. The microbiology analysis at 26 weeks showed that no bacteria were isolated. All the defects at the drilled site of the distal femurs of the NZWRs were united at 12 weeks interval. The histological examination revealed healing of the infected area with the appearance of a new bone formation at 6 to 26 weeks. The micro-CT results revealed increased the trabeculae numbers with the treatments. The biomaterials containing CaSO<sub>4</sub> disappeared by 26 weeks. There was completed bone healing at 26 weeks of interval for both groups. The results of the gentamicin impregnated with HA and CaSO<sub>4</sub> for all parameters are comparable. Hence, the antibiotics impregnated with biomaterials are proven effective in the treatments of osteomyelitis. In conclusion, the results of this study show that gentamicin impregnated with biomaterial has a great potential to be utilised for the treatment of osteomyelitis.

## خلاصة البحث

دراسه مقارنه حول طرق علاج مبتكره لإيصال الدواء، المضاد الحيوي، موضعيا الى منطقة التهاب وحمج العظم المستحدث في حيوان التجارب الارنب النيوزيلندي الأبيض ما يزال علاج التهاب العظم الجرثومي من التحديات الكبيرة التي تواجه العاملين في جراحة العظام والكسور. ان الارنب النيوزيلندي الأبيض يعتبر حيوان تجارب مناسب لهذا الغرض حيث يمكن استعماله في تجارب إيصال الدواء الى مكان التهاب وتخرم العظم بصورة مماثلة لما يحدث في الإنسان. ان غاية هذا البحث إحداث اصابه بالتهاب العظم الجرثومي في عظم الفخذ للارنب ومن ثم علاجه بحبيبات مواد بيولوجيه مخصبه (مشبعه) بالمضاد الحيوي جنتاميسين، وتحليل النتائج المترتب. أحدث التهاب العظم بعمل ثقب في اسفل عظم فخذ الارنب النيوزيلندي الأبيض وبعدها زرقت البكتريا العنقودية الذهبية في الثقب. تراوح وزن الارانب المستعمله في البحث ما بين 2.5 - 4.2 كغم وكانت جميعها بعمر اكثر من ستة أشهر. استعمل 36 حيوان لهذه الدراسة وقد قسمت الحيوانات الى مجموعته خادعه من اربع حيوانات بدون علاج، ومجموعتين أخريين من اربع أرناب لكل منهما خضعتا للعلاج، احدهما عولجت بهيدروكسيد الاباتيت والأخرى بسلفات الكالسيوم المخصبتين بالجنتاميسين. قسمت كل من المجموعتين من الحيوانات التي خضعت للعلاج الى أربعة مجاميع صغرى لكل منهما، احتوت الواحده على 4 ارناب ضحي بها على فترات هي 3, 6, 12 و 26 اسبوع بعد بدأ العلاج. أجريت عمليتين جراحيتين لكل ارناب، الأولى لاحداث التلوث الجرثومي والأخرى للتنظيف الجراحي وزرع حبيبات المواد البيولوجيه المشبعه بالمضاد الحيوي جنتاميسين. تم تقييم نتائج العلاج بحبيبات هيدروكسيد الاباتيت ومقارنته بالعلاج بكبريتات الكالسيوم المشبعتين بالمضاد الحيوي عن طريق دراسة الأعراض المرضيه في الجسم، التصوير بأشعة اكس، التصوير الشعاعي المقطعي الدقيق بالاضافه للدراسه الجرثوميه والنسيجييه في نهاية الأسبوع الثالث، السادس، الثاني عشر والسادس والعشرون من بدأ العلاج، قبيل التضحية بها لتقييم سيرعملية شفاء الخمج العظمي. بينت النتائج حصول التهاب العظم الجرثومي في الاسبوع الثالث في جميع مجموعات الارانب التي خضعت لعملية حقن البكتريا في العظم. نقص وزن في الاسبوع الثالث بعد الاصابه ولكن الارانب المصابه بدرجة ملحوظه وذات مغزى احصائيفي الاسبوع 12 مجموعتي المعالجه ازيد وزنهما بدرجة ملحوظه وذات مغزى احصائيو 26 بعد العلاج بالمادتين البيولوجيه المشبعه بالمضاد الحيوي. تم التأكد مختبريا من القضاء كليا على البكتريا المخمجه للعظم في الأسبوع 26 من بدأ العلاج. وقد تبين نسيجيا ان جميع ثقب العظام قد التئمت في الأسبوع 12 في الحيوانات المعالجه، وقد كانت هناك بوادر شفاء في المناطق المصابه من خلال تكون نسيج عظمي جديد منذ الأسبوع السادس واستمر حتى نهايته التجارب في الأسبوع السادس والعشرين. بينت نتائج الفحص الشعاعي المقطعي الدقيق ان عدد الترايبق العظميه ازيد بنسب ذات مغزى احصائ في مجاميع المعالجه مقارنة بالمجموعه الخادعه. ان ماده العضويه المستعمله في العلاج قل تواجدها بمرور الوقت واختفت في الأسبوع 26. لم نجد فروقات ذات مغزى احصائ بين نتائج الفحوصات الشعاعيه، النسيجييه التصوير الشعاعي المقطعي الدقيق الخ بين مجموعتي العلاج بكبريتات الكالسيوم والأخرى بهيدروكسيد الاباتيت المشبعتين بالجنتاميسين حيث ان كلاهما أعطى نتائج متماثلة في علاج التهاب وحمج العظم المستحدث في حيوان التجارب الارنب النيوزيلندي الأبيض. نستنتج من هذه الدراسة ان العلاج بهيدروكسيد الاباتيت المشبع بالجنتاميسين له الامكانيه بأن يستعمل سريريا كطريق لإيصال الدواء موضعيا لمعالجه الخمج البكتيري للعظم، وذلك بعد إجراء فحوصات مقارنه أخرى والتأكد من سلامته من المضاعفات

## APPROVAL PAGE

The thesis of Ahmad Hafiz Zulkifly has been approved by the following:

---

Mohammed Imad A. Mustafa Mahmud  
Supervisor

---

Nasser Mohammad Amjad  
Co-Supervisor

---

Naznin Muhammad  
Internal Examiner

---

Mohamed Abd Razak  
External Examiner

---

Habsah Hassan  
External Examiner

---

Zarina Zainuddin  
Chairman


## DECLARATION

I hereby declare that this thesis is the result of my own investigation, except where otherwise stated. I also declare that it has not been previously or concurrently submitted as a whole for any other degrees at IIUM or other institutions.

Ahmad Hafiz Zulkifly

Signature.....

Date.....



**INTERNATIONAL ISLAMIC UNIVERSITY MALAYSIA**

**DECLARATION OF COPYRIGHT AND AFFIRMATION OF  
FAIR USE OF UNPUBLISHED RESEARCH**

**A STUDY ON GENTAMICIN IMPREGNATED BIOMATERIALS  
FOR TREATING INDUCED -OSTEOMYELITIS IN THE NEW  
ZEALAND WHITE RABBIT ANIMAL MODEL**

I declare that the copyright holder of this thesis is International Islamic University  
Malaysia.

Copyright© 2021 by Ahmad Hafiz Zulkifly and International Islamic University  
Malaysia. All rights reserved.

No part of this unpublished research may be reproduced, stored in a retrieval  
system, or transmitted, in any form or by any means, electronic, mechanical,  
photocopying, recording or otherwise without prior written permission of the  
copyright holder except as provided below.

1. Any material contained in or derived from this unpublished research  
may be used by others in their writing with due acknowledgement.
2. IIUM or its library will have the right to make and transmit copies (print  
or electronic) for institutional and academic purposes.
3. The IIUM library will have the right to make, store in a retrieval system  
and supply copies of this unpublished research if requested by other  
universities and research libraries.

By signing this form, I acknowledged that I have read and understand the IIUM  
Intellectual Property Right and Commercialization policy.

Affirmed by Ahmad Hafiz Zulkifly

.....  
Signature

.....  
Date

## ACKNOWLEDGEMENT

With the Greatness and Mercy of ALLAH S.W.T and the grace and blessing from ALLAH S.W.T, Selawat and Salam for our beloved prophet Muhammad (SAW) and his companion. It was a very long journey to complete this study. It was very challenging. A lot of events took place and beyond the control.

I would like to thank my beloved mother Pn. Hajjah Maimunah bt. Yacob, my dearest, respected and loved wife Dr. Hajjah Rosmaliza bt. Ismail, my lovely, cute, inspirational son Ahmad Rayyan who was there during this long journey and unconditional love.

I wish to thank Prof. Dato' Dr. Tahir Azhar, our pioneer Dean of Medicine IIUM, who always inspire others to pursue knowledge. Gratitude to Prof. Dr. Nasarudin bin Abdullah, who believes that this journey can be successfully run although tough that the writer may not need extra qualifications. He agrees to be my supervisor when others denied. Thank you, Prof., Dr. Imad, my current supervisor who agree to continue with me the journey left by Prof. Nasa.

Similar gratitude to all my teachers since early days until now they have shown the path for a student to pursue and be success. My colleagues who give their trust and support during this study and journey. Thank you.

Special gratitude to my research team at my ISO 17025 Orthopaedic Advanced Research Lab esp: Mohd Zulfadzli Ibrahim, Nurul Hafiza Mohd Jan, Che Nor Zarida Che Seman, Rosnani Abdul Jalil, Dr. Aziah Aziz and others. I am also grateful to my students where I learned things that is not in the literature.

All the great occasions were by the willing of the Almighty ALLAH S.W.T. I would like to say ALHAMDULILLAH with all His Mercy, kindness and blessings, this study was completed. Thank you all, Thank you ALLAH. Selawat and Salam to Prophet Muhammad S.A.W and Alhamdulillah.

# TABLE OF CONTENTS

Abstract.....	ii
Abstract in Arabic.....	iii
Approval Page.....	iv
Declaration.....	v
Copyright.....	vi
Acknowledgement.....	vii
Table of Contents.....	viii
List of Tables.....	xii
List of Figures.....	xiii
List of Abbreviations.....	xix
List of Symbols.....	xxii
<b>CHAPTER ONE :INTRODUCTION.....</b>	<b>1</b>
1.1 Background of the Study.....	1
1.2 Rationale of the Study.....	5
1.3 Objective.....	5
1.3.1 General Objective.....	5
1.3.2 Specific Objective.....	5
<b>CHAPTER TWO : LITERATURE REVIEW.....</b>	<b>7</b>
2.1 Overview of bone anatomy and histology.....	7
2.1.1 Composition.....	7
2.1.2 Bone Cells.....	8
2.2 Osteomyelitis.....	9
2.2.1 Overview of Osteomyelitis.....	9
2.2.2 Organisms in Osteomyelitis.....	13
2.3 Treatment of osteomyelitis.....	17
2.4 Drug delivery system.....	17
2.4.1 Drug Delivery.....	18
2.5 Biomaterials.....	20
2.5.1 Hydroxyapatite.....	20
2.5.2 Calcium Sulphate.....	21
2.6 Antibiotics.....	21
2.6.1 Gentamicin Sulphate.....	22
2.6.2 The Local Antibiotic Delivery System.....	23
2.6.3 Antimicrobial Agent in Local Delivery Systems.....	24
2.7 Animal model for osteomyelitis.....	24
2.7.1 Effectiveness of Treatment for New Zealand White Rabbit Model.....	26
2.7.1.1 Weight.....	26
2.7.1.2 Gross Inspection.....	27
2.7.1.3 Microbial Assessment.....	27
2.7.1.4 Plain Radiograph.....	27
2.7.1.5 Micro Computed-Tomography.....	27
2.7.1.6 Histology.....	28

2.8 Isolation and Identification of <i>S. aureus</i> .....	28
2.8.1 Bacterial Inoculation .....	28
2.8.2 Gram Staining .....	29
2.8.3 Catalase Test .....	29
2.8.4 Coagulase Test .....	29
<b>CHAPTER THREE: METHODOLOGY.....</b>	<b>31</b>
3.1 Animal Model.....	31
3.1.1 Ethical Approval .....	31
3.1.2 Study Design .....	31
3.1.3 Housing and Husbandry.....	33
3.1.4 Inclusion Criteria.....	34
3.1.5 Exclusion Criteria.....	35
3.2 Bacteria Inoculation.....	35
3.2.1 Preparation of Suspension of Bacteria .....	35
3.3 Preparation of Impregnated Biomaterial .....	37
3.3.1 Preparation of Gentamicin .....	37
3.3.2 Preparation of Starch Solution .....	37
3.3.3 Preparation of Gentamicin Impregnated with HA (Patent Pending Without Prejudice).....	37
3.3.4 Preparation of Impregnated Calcium Sulphate with Gentamicin ....	38
3.4 Approach of Surgery.....	39
3.4.1 Preoperative Preparation .....	39
3.4.1.1 Animal Operation Room.....	39
3.4.1.2 Environmental Conditions in Animal Operation Room .....	40
3.4.1.3 Preparation of Ketamine-Tiletamine-Xylazine Mixture Drugs (Anaesthesia).....	40
3.4.1.4 Animal Preparation and Cleaning of Operation Site .....	42
3.4.2 Operative Procedures .....	43
3.4.2.1 Inoculation of Bacteria.....	43
3.4.2.2 Insertion of Treatment (Gentamicin Impregnated with biomaterials) .....	45
3.4.3 Intra Operative Care .....	46
3.4.4 Post-Operative.....	46
3.5 Euthanasia.....	47
3.6 Assessments and Sample Processing.....	49
3.6.1 Radiographic Evaluation.....	50
3.6.2 Micro-CT Construct .....	51
3.6.2.1 Scanning Sample.....	52
3.6.2.2 Reconstruction of Sample .....	53
3.6.2.3 CT Analyzer.....	55
3.6.3 Microbial Analysis .....	56
3.6.3.1 Gram Staining Technique .....	57
3.6.3.2 Catalase Test .....	58
3.6.3.3 Coagulase Test .....	59
3.6.4 Histology Interpretation (Undecalcified Tissue Processing) .....	60
3.6.4.1 Sample Grossing .....	60
3.6.4.2 Fixation and Processing .....	61
3.6.4.3 Embedding and Polymerization .....	62
3.6.4.4 Sample Block and Slide Preparation.....	64

3.6.4.5 Staining .....	67
3.7 Statistical Tools .....	69
<b>CHAPTER FOUR: RESULT .....</b>	<b>70</b>
4.1 Overview.....	70
4.2 Comparison of Weight Between Groups.....	70
4.2.1 Rabbit Weight before & after OM and Implant.....	70
4.3 Gentamicin Impregnated Calcium Sulphate and Gentamicin Impregnated Hydroxyapatite Groups.....	75
4.3.1 Gentamicin Impregnated CaSO <sub>4</sub> and Gentamicin Impregnated HA .....	75
4.4 Culture result .....	76
4.4.1 Results of Microbial Assessments .....	77
4.4.1.1 Sham Group .....	77
4.4.1.2 3 Weeks of Treatment.....	78
4.4.1.3 6 Weeks of Treatment.....	80
4.4.1.4 12 Weeks of Treatment.....	81
4.4.1.5 26 Weeks of Treatment.....	82
4.4.2 Summary of Microbial Study.....	83
4.5 Gross Assessment of the Bone .....	85
4.5.1 Gross Evaluation (HA vs Calcium Sulphate).....	85
4.5.1.1 Sham and Normal Group .....	85
4.5.1.2 3 Weeks Post-Operative.....	86
4.5.1.3 6 Weeks Post-Operative.....	87
4.5.1.4 12 Weeks Post Operative.....	88
4.5.1.5 26 Weeks Post-Operative.....	89
4.5.2 Summary of Gross Examination Study.....	90
4.6 Radiographic Evaluation .....	91
4.6.1 Radiographic Score Scale .....	91
4.6.1.1 Radiographic Score Scale according to Ambrose et al., 2004 .....	91
4.6.2 Radiographic Evaluation (HA vs. CaSO <sub>4</sub> ).....	92
4.6.2.1 Sham and Normal Group .....	92
4.6.2.2 3 Weeks Post-Operative.....	93
4.6.2.3 6 Weeks Post-Operative.....	94
4.6.2.4 12 Weeks Post-Operative.....	95
4.6.2.5 26 Weeks Post-Operative.....	96
4.6.3 Summary of Radiological Study .....	97
4.7 Micro-CT .....	98
4.7.1 The results in Micro-CT Evaluation of the experimental animal groups (all groups) .....	98
4.7.2 Micro-CT 3D Analysis.....	100
4.7.2.1 Sham Procedure and Control .....	100
4.7.2.2 3 Weeks Post-Treatment Assessment .....	101
4.7.2.3 6 Weeks Post-Treatment Assessment .....	102
4.7.2.4 12 Weeks Post-Treatment Assessment .....	103
4.7.2.5 26 Weeks Post-Treatment Assessment .....	104
4.7.3 Summary of Micro-CT 3D Analysis Study .....	105
4.7.4 Micro-CT 2D Analysis.....	106
4.7.4.1 3 Weeks Post-Treatment Assessment .....	106

4.7.4.2 6 Weeks Post-Treatment Assessment .....	107
4.7.4.3 12 Weeks Post-Treatment Assessment .....	108
4.7.4.4 26 Weeks Post-Treatment Assessment .....	109
4.7.5 Summary of Micro-CT 2D Analysis Study .....	109
4.8 Histological Assessment .....	111
4.8.1 Histology Evaluation (Modified Oderkeken et. al., 2013).....	111
4.8.2 Morphology and Histological Evaluation (Masson-Goldner Method) .....	112
4.8.2.1 Sham Procedure and Control .....	112
4.8.2.2 3 Weeks Post-Treatment Assessment .....	113
4.8.2.3 6 Weeks Post-Treatment Assessment .....	114
4.8.2.4 12 Weeks Post-Treatment Assessment .....	115
4.8.2.5 26 Weeks Post-Treatment Assessment .....	116
4.8.3 Summary of Histology Evaluation Analysis Study .....	116
<b>CHAPTER FIVE : DISCUSSION.....</b>	<b>118</b>
5.1 Overview.....	118
5.2 Animal model .....	119
5.3 Surgical Approach .....	121
5.3.1 Observation Time Points.....	122
5.4 Bone Healing Assessments.....	122
5.4.1 Plain Radiograph.....	122
5.4.2 Micro-Computed Tomography .....	123
5.4.3 Microbiological Analysis .....	124
5.4.4 Gross Assessment .....	125
5.4.5 Histological .....	126
5.5 Gentamicin Impregnated With Biomaterials .....	127
5.5.1 Biomaterials .....	127
5.5.2 Gentamicin .....	128
5.6 Limitation of the Study .....	129
<b>CHAPTER SIX : CONCLUSION AND FUTURE STUDY .....</b>	<b>130</b>
6.1 Conclusion .....	130
6.2 Recommendations on Further Evaluation Parameter .....	130
6.2.1 Biocompatibility Study .....	130
6.2.2 Clinical Trial .....	130
6.2.3 Application to be Patented .....	131
<b>REFERENCES.....</b>	<b>132</b>
<b>APPENDIX 1: ANIMAL ETHIC APPROVAL LETTER.....</b>	<b>162</b>
<b>APPENDIX 2: ISO/IEC 17025:2005 REASSESEMENT.....</b>	<b>163</b>
<b>APPENDIX 3: TEST REPORT OF ANTIMICROBIAL STUDY.....</b>	<b>164</b>
<b>APPENDIX 4: TEST REPORT OF DRUG RELEASE STUDY .....</b>	<b>175</b>
<b>APPENDIX 5: FULL ARTICLES/PROCEEDINGS/ABSTRACTS         CONTRIBUTED TO THIS THESIS .....</b>	<b>182</b>
<b>APPENDIX 6: AWARDS.....</b>	<b>190</b>

## LIST OF TABLES

Table 3.1	Anaesthetic regime for a combination of ketamine, tiletamine/zolazepam and xylazine	41
Table 3.2	Radiographic Grading Scale (Ambrose, 2004)	50
Table 3.3	Osteomyelitis Scoring System for micro-CT (Odekerken et al., 2013)	51
Table 3.4	Osteomyelitis Scoring System for histology through Masson Goldner Staining (Odekerken et al., 2013)	66
Table 4.1	Comparison scores a defect area in radiographic between gentamicin impregnated with CaSO <sub>4</sub> and gentamicin impregnated with HA (Ambrose et al., 2004).	89
Table 4.2	Comparison between the micro-CT evaluation of gentamicin impregnated with CaSO <sub>4</sub> and gentamicin impregnated with HA group by using the Kruskal-Wallis test.	104
Table 4.3	The comparison was between 3 weeks post inoculation (before) and week of implantation of Gentamicin impregnated HA (after) in the histological evaluations by using Mann Whitney U test.	109
Table 4.4	The comparison was between 3 weeks post inoculation (before) and week of implantation of Gentamicin impregnated CaSO <sub>4</sub> (after) in the histological evaluations by using Mann Whitney U test.	117

## LIST OF FIGURES

Figure 3.1	An overview of the experimental study design.	33
Figure 3.2	Housing for the rabbit a) rabbit in the cage b) animal house	34
Figure 3.3	Bacteria strain (a) <i>Staphylococcus aureus</i> with number ATCC 25923 (b) Bacteria in nutrient broth culture	35
Figure 3.4	Figure 3.4 Graph shows the relation between absorbance reading and CFU of the bacteria. The dilution 1/16 bacteria solution (with red line) was showed the reading of $2.0 \times 10^6$ .	36
Figure 3.5	Steps for agar preparation.	37
Figure 3.6	Freeze dryer machine.	38
Figure 3.7	Preparation of antibiotics (a) Gentamicin in powder form (b) Gentamicin solution mixed with biomaterials (calcium sulphate or HA) paste and starch (c) Mixture were placed into the mould (d) Local antibiotic in beads form.	39
Figure 3.8	a) Layout the surgical instruments on the table during surgery b) Operating room	40
Figure 3.9	a) Premedication via intramuscular injection b) Intravenous anaesthesia during surgery.	42
Figure 3.10	Prior to surgery, the site was shaved.	42
Figure 3.11	The procedure in inoculation of bacteria to induced osteomyelitis. a) rabbit on the operating table b) skin incision made over lateral aspect distal femur c) femur drilled with 3.0mm drill d) hole over the femur e) needle showing medullary canal f) femoral shaft washed with 50 ml distilled water g) 0.2 ml of $2 \times 10^6$ colony-forming units of <i>S. aureus</i> was injected into the medullary canal with sterile needle 23G h) The fascia closed in 1 layer with Safil 3/0 i) Skin was closed in 2 layers, to prevent wound breakdown with Safil 3/0.	44
Figure 3.12	Procedures for antibiotic insertion a) Pus coming out from the osteomyelitis area b) unhealthy tissue removed c) swab culture was taken and incubated for 24 hours d) intramedullary canal washed with normal saline e) antibiotic beads	46
Figure 3.13	Wound after two weeks of surgery.	47
Figure 3.14	Euthanasia procedure (a) Monitoring the rabbit pulse rate during euthanasia (b) The rabbit was death as the pulse meter show no reading	48

Figure 3.15	Photograph illustrating harvesting procedure (a) Incision of the skin using a scalpel (b) Cutting the muscle layer apart to expose the bone (c) Harvesting the sample (d) Swabbing sample on plain agar media (e) Sample ready for processing	49
Figure 3.16	X-ray procedures (a) The rabbit was put at the left position for capturing the radiographic image (b) Close-up view	50
Figure 3.17	An overview step for Micro-CT scanning.	52
Figure 3.18	The typical appearance of NRecon <sup>®</sup> during the reconstruction process.	53
Figure 3.19	The Output page with preview display mode.	53
Figure 3.20	An overview step for reconstruction.	54
Figure 3.21	An overview step for CT analyser.	55
Figure 3.22	a) Nutrient agar b) Culture in the petri dish c) <i>Staphylococcus aureus</i> , gram-positive cocci under light microscope 1000X magnification.	57
Figure 3.23	Bubbles on the slide with the tested organism	58
Figure 3.24	Clumping on the slide for coagulase producing organism	58
Figure 3.25	Harvesting procedures (a-b) Photograph show the sample-harvesting procedure	59
Figure 3.26	Washing of sample (a-b) under running tap water	60
Figure 3.27	Dehydration and infiltration process (a) Leica automated tissue processor (b) Samples are ready for processing	60
Figure 3.28	Embedding of samples (a) The Samples were embedded in hydroxyethyl methacrylate, (b) Samples were vacuumed to remove air bubbles, (c) The samples were polymerised under yellow light, (d) yellow light close-up view, (e) The samples were polymerised under blue light, (f) blue light close-up view, (g) Polymerised block was done	62
Figure 3.29	Summaries of steps from sample sectioning up to the slide preparation in undecalcified histology tissue processing (a) The polymerised blocks were cut and fashioned according to the shape of sample, (b) The set of Technovit <sup>®</sup> 4000, (c) The samples were stick using Technovit cement to the Perspex slide, (d) The samples were cut to get a flat surface (course cutting)	63
Figure 3.30	Flowchart of steps for preparing the undecalcified bone specimens	63

Figure 3.31	Slide sectioning and grinding process (a) EXAKT cutter machine (b) sectioning slide with EXAKT cutter machine (c) Micro-grinding machine (d) Grinding slide with micro grinding machine	64
Figure 3.32	Flowchart of steps for undecalcified bone slides	65
Figure 3.33	Masson Goldner Staining Kit	65
Figure 3.34	Nikon Eclipse <i>Ni</i> motorised microscope with an image analyser	66
Figure 4.1	Graph showed the comparison of weight in both groups at 3 weeks assessment. The blue line represents for gentamicin impregnated CaSO <sub>4</sub> treatment, and green line represent for gentamicin impregnated HA treatment. Time 1 = prior to surgery and inoculation of bacteria, Time 2 = 3 weeks post-inoculation of bacteria, Time 3 = 3 weeks post-treatment.	70
Figure 4.2	Graph showed the comparison of weight in both groups at 6 weeks assessment. The blue line represents for gentamicin impregnated CaSO <sub>4</sub> treatment and green line represent for gentamicin impregnated HA treatment. Time 1 = prior to surgery and inoculation of bacteria, Time 2 = 3 weeks post-inoculation of bacteria, Time 3 = 6 weeks post-treatment.	71
Figure 4.3	Graph showed the comparison of weight in both groups at 12 weeks assessment. The blue line for gentamicin impregnated CaSO <sub>4</sub> treatment and green line represent for gentamicin impregnated HA treatment. Time 1 = prior to surgery and inoculation of bacteria, Time 2 = 3 weeks post-inoculation of bacteria, Time 3 = 12 weeks post-treatment.	72
Figure 4.4	Graph showed the comparison of weight in both groups at 26 weeks assessment. The blue line represents for gentamicin impregnated CaSO <sub>4</sub> treatment, and green line represent for gentamicin impregnated HA treatment. Time 1 = prior to surgery and inoculation of bacteria, Time 2 = 3 weeks post-inoculation of bacteria, Time 3 = 26 weeks post-treatment.	73
Figure 4.5	Antibiotic disc diffusion test. The beads tested are CaSO <sub>4</sub> containing gentamicin, HA containing gentamicin, HA only and CaSO <sub>4</sub> only	74
Figure 4.6	Process for confirmation of <i>Staphylococcus aureus</i> a) Culture on nutrient agar b) <i>Staphylococcus aureus</i> , gram-positive cocci under light microscope 1000X magnification c) Catalase test showed bubbles formation d) Coagulase test showed clumping of plasma.	75
Figure 4.7	Growth was noted at the sham group after three weeks of inoculation.	76

Figure 4.8	The culture growth becomes lesser compared to the sham group after week 3 of gentamicin impregnated with biomaterials.	77
Figure 4.9	The culture growth become lesser after six weeks of implantation of gentamicin impregnated with biomaterials.	78
Figure 4.10	The growth become lesser after received week 12 of treatment with gentamicin impregnated biomaterials.	79
Figure 4.11	After week 26 of treatment, there is no growth noted at culture analysis.	80
Figure 4.12	Summary of microbial study from week 3 to week 26 of post-treatment	82
Figure 4.13	A) Sham Procedure, (B) Normal bone	83
Figure 4.14	A) The femur treated with gentamicin impregnated HA (B) The femur treated with gentamicin impregnated CaSO <sub>4</sub>	84
Figure 4.15	A) The femur treated with gentamicin impregnated HA (B) The femur treated with gentamicin impregnated CaSO <sub>4</sub>	85
Figure 4.16	The femur treated with gentamicin impregnated HA (B) The femur treated with gentamicin impregnated CaSO <sub>4</sub>	86
Figure 4.17	(A) The femur treated with gentamicin impregnated HA (B) The femur treated with gentamicin impregnated CaSO <sub>4</sub>	87
Figure 4.18	Summary of gross examination from week 3 to week 26 of post-treatment	88
Figure 4.19	Radiographs images of the femurs in Sham Group (A) and a normal femur of NZWR (B).	90
Figure 4.20	(A) Radiograph image of the femur treated with gentamicin impregnated HA at 3 weeks (B) Radiograph of the femur treated with gentamicin impregnated CaSO <sub>4</sub> at 3 weeks.	91
Figure 4.21	Radiograph images of the femurs treated with gentamicin impregnated HA (A) and gentamicin impregnated CaSO <sub>4</sub> (B) at 6 weeks.	92
Figure 4.22	A) Radiograph image of the femur treated with gentamicin impregnated HA at 12 weeks (B) Radiograph of the femur treated with gentamicin impregnated CaSO <sub>4</sub> at 12 weeks.	93
Figure 4.23	(A) Radiograph image of the femur treated with gentamicin impregnated HA at 26 weeks (B) Radiograph of the femur treated with gentamicin impregnated CaSO <sub>4</sub> at 26 weeks.	94
Figure 4.24	The radiological images from 3 weeks to 26 weeks post-treatment	95
Figure 4.25	Micro-CT 3D analysis for the sham group showing bone swelling and defect <i>in situ</i> .	98

Figure 4.26	Micro-CT analysis for three weeks of the treatment group. A) Treatment with gentamicin impregnated HA B) Treatment with gentamicin impregnated CaSO <sub>4</sub> .	99
Figure 4.27	Micro-CT analysis for six weeks of the treatment group. A) Treatment with gentamicin impregnated HA B) Treatment with gentamicin impregnated CaSO <sub>4</sub> .	100
Figure 4.28	Micro-CT analysis for week 12 of the treatment group. A) Treatment with gentamicin impregnated HA B) Treatment with gentamicin impregnated CaSO <sub>4</sub> .	101
Figure 4.29	Micro-CT analysis for week 26 of the treatment group. A) Treatment with gentamicin impregnated HA B) Treatment with gentamicin impregnated CaSO <sub>4</sub> .	102
Figure 4.30	Summary of Micro-CT 3D analysis from week 3 to week 26 of post-treatment	103
Figure 4.31	Micro-CT analysis for 3 weeks of the treatment group. A) Treatment with gentamicin impregnated HA B) Treatment with gentamicin impregnated CaSO <sub>4</sub>	104
Figure 4.32	Micro-CT analysis for 6 weeks of the treatment group. a) Treatment with gentamicin impregnated HA b) Treatment with gentamicin impregnated CaSO <sub>4</sub>	105
Figure 4.33	Micro-CT analysis for 12 weeks of the treatment group. A) Treatment with gentamicin impregnated HA B) Treatment with gentamicin impregnated CaSO <sub>4</sub>	106
Figure 4.34	Micro-CT analysis for 26 weeks of the treatment group. a) Treatment with gentamicin impregnated HA b) Treatment with gentamicin impregnated CaSO <sub>4</sub>	107
Figure 4.35	Micro-CT 2D analysis from week 3 to 26 week of post-treatment	108
Figure 4.36	Histological images of (A) the normal bone and (B) Sham procedures. (Masson Goldner Trichrome stain, original magnification 40X).	110
Figure 4.37	Histology images at 3 weeks of post-treatment groups. (A) Treatment with gentamicin impregnated HA (B) Treatment with gentamicin impregnated CaSO <sub>4</sub> . (Masson Goldner Trichrome stain, original magnification 40X).	111
Figure 4.38	Histology images at 6 weeks of the post-treatment groups. (A) Treatment with gentamicin impregnated HA (B) Treatment with gentamicin impregnated CaSO <sub>4</sub> . (Masson Goldner Trichrome stain, original magnification 40X).	112

Figure 4.39	Figure 4.39 Histology images at 12 weeks post-treatment groups. (A) Treatment with gentamicin impregnated HA (B) Treatment with gentamicin impregnated CaSO <sub>4</sub> (Masson Goldner Trichrome stain, original magnification 40X).	113
Figure 4.40	Figure 4.40 Histology images of 26 weeks of the post-treatment groups. (A) Treatment with gentamicin impregnated HA (B) Treatment with gentamicin impregnated CaSO <sub>4</sub> . (Masson Goldner Trichrome stain, original magnification 40X).	114
Figure 4.41	Histology evaluation analysis from week 3 to week 26 of post-treatment	115




## LIST OF ABBREVIATIONS

2D	2-Dimension
3D	3-Dimension
AG	German Aktiengesetz
ANOVA	Analysis of Variance
ATCC	American Type Culture Collection
BEM	Bone Extracellular Matrix
BMD	Bone Mineral Density
BR	Basic Research
BS	Bone Surface
BS/TV	Bone Surface Ratio
BV	Volume of Trabeculae
BV/TV	Bone Volume
CaSO <sub>4</sub>	Calcium Sulphate
CD	Compact Disc
CHA	Calcium Hydroxyapatite
Co.	Company
CT	Computed Tomography
DDS	Drug Delivery System
DNA	Deoxyribonucleic Acid
EDTA	Ethylenediaminetetraacetic Acid
EPS	Exopolysaccharides
FOV	Field of View
HA	Hydroxyapatite
IACUC	Institutional Animal Care and Use Committee

IBM	IBM Corporation
IIUM	International Islamic University Malaysia
IQR	Interquartile Range
ISO/IEC	International Organization for Standardization / International Electrotechnical Commission
IV	Intravenous
KTX	A combination of drugs Ketamine, Tiletamine / Zolazepam and Xylazine for anaesthesia
MIC	Minimum Inhibitory Concentrations
Micro-CT	Micro-Computed Tomography
MOSTI	Minister of Science, Technology and Innovation
NBF	Natural Buffered Formalin
NZWR	New Zealand White Rabbit
OM	Osteomyelitis
OM	Osteomyelitis
PMMA	Poly (methyl methacrylate)
POP	Plaster of Paris
PPB	Part per Billion
Pty Ltd.	Propriety / Private Limited
qPCR	Quantitative Polymerase Chain Reaction
ROI	Region of Interest
<i>S. aureus</i>	<i>Staphylococcus aureus</i>
SPO <sub>2</sub>	Blood Oxygen Saturation
SPSS	Statistical Package for the Social Science
Tb. N	Trabecular Number
Tb. Th	Trabecular Separation
TRAP	Tartrate-resistant Acid Phosphate

TSA                    Tryptic Soy Agar  
TV                     Total Volume  
USA                    United States of America



## LIST OF SYMBOLS

%	Percentage
<	Less than
=	Equal to
≠	Not equal to
>	More than
±	Standard deviation
≤	Less than or equal to
≥	More than or equal to
®	Registered patent
°C	Degree Celsius
μA	Microampere
μg/ml	Microgram per millilitre
μm	Micrometre
1 <sup>st</sup>	First
CFU/ml	Colony-forming units per millilitre
cm	Centimetre
cm <sup>2</sup>	Square Centimetre
CO <sub>2</sub>	Carbon dioxide
<i>df</i>	Degree of freedom
F	Fisher–Snedecor distribution
g	Gram
g/ml	Gram per millilitre
Ha	Alternative Hypothesis
Ho	Null Hypothesis

kg	Kilogram
kV	Kilovolt
M	Mean
MD	Mean Different
mg	Milligram
mg/ml	Milligram per Millilitre
ml	Millilitre
ml/kg	Millilitre per Kilogram
mm	Millimetre
mM	Millimolar
mm <sup>3</sup>	Cubic Millimetre
mmHg	Millimetre Mercury
ms	Millisecond
NaCl	Natrium Chloride
rpm	Rotation per Minute
SD	Standard Deviation
SE	Standard Error
™	Trademark
v/v	Volume per Volume
w/v	Weight / Volume
w/w	Weight per Weight
Z	Normal Distribution Score
$\eta^2p$	Effect Size
$\chi^2$	Chi-squared Test
%	Percentage

# CHAPTER ONE

## INTRODUCTION

### 1.1 BACKGROUND OF THE STUDY

Osteomyelitis (OM) is a progressive bone infection that results from inflammatory destruction of the bone, necrosis of bone, and new bone formation, and may progress to a chronic and persistent state. It can be divided into acute, subacute, and chronic osteomyelitis. However, as described in the literature, there are many ways to classify osteomyelitis (Hotchen et al., 2017). These classification systems help to define the infection and determine the need for surgery. Chronic osteomyelitis is one of the most severe complications of orthopaedic open fracture treatment (Kuehl et al., 2016; Panteli et al., 2016). Osteomyelitis is usually caused by bacteria and sometimes by fungus. The infection causes the inflammation of bone and bone marrow. Thick walls surround the soft tissue of bone and inflammation at the surrounding tissues cause circulatory distractions, which can promptly lead to necrosis of various parts of the bone. These necrotic bones act as a non-living surface for the attachment of bacteria and the formation of biofilm. The bones that are most commonly affected, include the femur, tibia, and humerus, although nearly all bones in the body can be involved. As a consequence, the disease tends to be both localized and generalized because the bacteria can be carried to other organs (Hotchen et al., 2017; Kuehl et al., 2016; Panteli et al., 2016).

The predominant aetiological agents of chronic osteomyelitis are *Staphylococcus aureus* (*S. aureus*), Group A beta-hemolytic Streptococcus, and gram-negative bacteria, particularly *Salmonella* spp., *Mycobacterium tuberculosis*, and *Pseudomonas aeruginosa* (Hotchen et al., 2017; Kuehl et al., 2016; Panteli et al., 2016). Previous